DB12016 (Ponesimod), an antagonist of sphingosine-1-phosphate receptor 1 (S1PR1), has shown potential in AD models by modulating microglial activity, alleviating neuroinflammation, and enhancing amyloid β clearance [107]. The gene discussed is S1PR1; the disease is Alzheimer disease.